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Abstract
Background: The complement system, a key component that links the innate and adaptive immune responses, has three
pathways: the classical, lectin, and alternative pathways. In the present study, we have analyzed the levels of various
complement components in blood samples from dengue fever (DF) and dengue hemorrhagic fever (DHF) patients and
found that the level of complement activation is associated with disease severity.
Methods and Results: Patients with DHF had lower levels of complement factor 3 (C3; p=0.002) and increased levels of C3a,
C4a and C5a (p,0.0001) when compared to those with the less severe form, DF. There were no significant differences
between DF and DHF patients in the levels of C1q, immunocomplexes (CIC-CIq) and CRP. However, small but statistically
significant differences were detected in the levels of MBL. In contrast, the levels of two regulatory proteins of the alternative
pathway varied widely between DF and DHF patients: DHF patients had higher levels of factor D (p=0.01), which cleaves
factor B to yield the active (C3bBb) C3 convertase, and lower levels of factor H (p=0.03), which inactivates the (C3bBb) C3
convertase, than did DF patients. When we considered the levels of factors D and H together as an indicator of (C3bBb) C3
convertase regulation, we found that the plasma levels of these regulatory proteins in DHF patients favored the formation
of the (C3bBb) C3 convertase, whereas its formation was inhibited in DF patients (p,0.0001).
Conclusion: The data suggest that an imbalance in the levels of regulatory factors D and H is associated with an abnormal
regulation of complement activity in DHF patients.
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Introduction
The complement system plays both effector and regulatory roles
in the innate and adaptative arms of the immune response. It is
also a key factor in integrating these two defense systems. As part
of the innate immune system, the complement system serves as the
first line of defense against infectious agents; while as part of the
adaptive immune system; it is involved in modulation of B- and T-
cell function, maturation, and immunological memory. The
complement system has been shown to have a complex role in
Flavivirus infections, being considered either protective, by limiting
viral replication, increasing the clearance of virus, and inhibiting
antibody-dependent enhancement (ADE); or deleterious, by
increasing disease severity when excessively activated, causing an
exacerbated inflammatory response [1,2]. The involvement of
augmented complement activation in dengue pathophisiolgy was
demonstrated by Bokisch et al. [3], however the specific
mechanisms triggering the increased complement activation in
dengue disease still need elucidation.
The complement system has three major pathways: the classical
(CP), the alternative (AP), and the lectin (LP)-dependent pathways.
The CP is often activated by antibody-antigen complexes [4] or by
the C-reactive protein (CRP) [5], both of which interact with
complement component C1q. In addition, the CP can be activated
by phosphatidyl serine present in apoptotic bodies [6] in the
absence of immune complexes. The LP is initiated by the
mannose-binding lectins (MBL) that bind to complex carbohy-
drate residues on the surface of pathogens. The activation of the
CP or the LP leads to activation of the (C4b2b) C3 convertase.
The AP is activated by the binding of C3b, which is spontaneously
generated by the hydrolysis of C3, on targeted surfaces. This
surface-bound C3b is then recognized by factor B, forming the
complex C3bB [7]. The C3bB complex, in turn, is cleaved by
factor D to yield the active form of the C3 convertase of the AP
(C3bBb). Both types of C3 convertases will cleave C3, forming
C3b. C3b then either binds to more factor B, enhancing the
complement activation through the AP (the so-called alternative or
amplification loop), or leads to the formation of the active C5
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triggers the late events that result in the formation of the
membrane attack complex (C5b-9).
Dengue virus is a Flavivirus with four antigenically distinct
serotypes (DENV-1 to DENV-4). Dengue virus infection is a global
public health concern, with an estimated incidence of 50–100
million cases of dengue fever (DF) that result in 500,000 clinical
cases of the life-threatening dengue hemorrhagic fever syndrome
(DHF) and 24,000 deaths annually. DHF is characterized by
vasculopathy, which results in a sudden plasma leakage that reduces
the blood volume and may produce hypovolemic shock (dengue
shock syndrome, DSS). The immunopathological mechanism
responsible for the increased disease severity associated with DHF
is only partially understood. Several lines of evidence have indicated
that non-neutralizing anti-dengueantibodies play a modulatory role
that involves ADE. However, other factors, including innate
immunity, have also been shown to modulate the clinical outcome
[8–10], and several studies have shown that complement factors are
involved [11]. In a pioneering study, Bokisch et al. [3] measured the
levels of nine complement factors (C1q, C1s, C2, C3, C4, C5, C6,
C8 and factor B) in serum samples of DHF patients (grades I to IV).
They found that levels of C3 were reduced in all DHF patients, and
observed a correlation between C3 consumption and disease
severity. In addition, the levels of C4 and factor B were reduced
in the more severe DHF patients (grades III and IV). The authors
observed a correlation between levels of C3 with the levels of factor
B and C4 and based on these correlations the authors demonstrated
the direct involvement of both the classical and the alternative
pathwaysindengueseverity.However,neitherthelevelsofC1qand
C1s, nor the catabolic rate of C1q degradation presented a
significant correlation with disease severity [3].
Other studies have shown that the dengue non-structural (NS)-1
protein can directly activate the complement cascade in the
absence of antibody, and this activation is enhanced when anti-
dengue antibodies are present [11]. In addition, clinical studies
have shown that the levels of dengue NS1 and products of
complement activation, including those with a known vascular
effect, such as C3a, C5a, and sC5b-9, are present in higher levels
in DHF patients before plasma leakage takes place, supporting the
theory that complement activation is involved in the development
of severe disease [12] and to deleterious patient outcomes
[11,13,14]. Interestingly, the NS1 protein of West Nile virus,
another flavivirus which does not normally induce vasculopathy,
has been shown to bind to complement regulatory factor H [15]
and use this mechanism as an immune evasion mechanism.
So far, it seems clear that the complement system is activated
during dengue infection [11,16]; however, it is not clear to what
extent each of the three pathways (the CP, LP, and AP) contribute to
the overallactivation of the complement system, or what mechanisms
are triggering the increased complement activation during dengue
infection. In order to elucidate the contribution of the complement
system to dengue clinical outcomes, we have quantified specific
components of each of the three complement system pathways and
compared their levels in dengue virus-infected patients with mild
disease (DF) or severe disease (DHF), at different stages of infection
(acute and convalescent), to those in normal volunteers. Our data
show an important correlation between imbalances in the levels of
factor H and factor D and increased dengue severity.
Methods
Patients
A cohort of suspected dengue cases admitted to three hospitals
in the city of Recife in the state of Pernambuco, Brazil, has been
established and described elsewhere [17]. Sequential blood
samples collected during the first 30 days after the onset of
symptoms were harvested and cryopreserved to supply serum and
plasma samples at different stages of the infection. Plasma was
collected in both heparin and citrate buffers and used according to
the assay requirements. Dengue diagnosis was performed by
combining virus isolation in C6/36 cells [18] and RT-PCR [19]
with anti-dengue IgM/IgG ELISA. The classification of primary
vs. secondary dengue infection was based on the kinetics of the
IgM and IgG response, according to the following criteria:
Primary infection was defined as the absence of specific anti-
dengue IgG antibodies in the first serum samples during the acute
phase, with IgM, virus, and/or viral RNA being detected and
followed by the presence of anti-dengue IgG in convalescence
serum samples. Secondary infection was defined as the detection of
specific anti-dengue IgG in the first acute sample and an absence
of anti-dengue IgM, associated with a positive RT-PCR and/or
virus isolation [17,20].
Dengue cases were clinically classified according to the World
Health Organization (WHO) criteria into DF and DHF. DF cases
were characterized by fever lasting up to 7 days and accompanied
by at least two of the following symptoms: headache, retro-orbital
pain, myalgia, arthralgia, and rash associated with a platelet level
above 100,000/mm
3. DHF cases were defined as having the same
clinical manifestations as those in DF, but with evidence of
hemorrhage, thrombocytopenia (platelet,100,000/mm
3), and
plasma leakage following deffervescence.
Since patient age, date of sample collection, and virus
serotype and genotype are factors that can affect complement
levels and potentially produce misleading results, we applied the
following criteria in selecting patients: a) confirmed infection
with the DENV-3 serotype (genotype III), b) age.=13years,
and c) availability of a blood sample collected within 3 to 8 days
of the onset of symptoms and defined as acute phase. A total of
74 dengue cases met the criteria: 47 patients with DF and 27
with DHF (grades I and II). In the case of the DF patients, 41%
o ft h ei n fe c t io n sw e rep ri ma rya n d5 9 %se c o n d ar y;i nt h ec a seo f
the DHF patients, 58% were primary and 42% secondary
(Table 1). A second set of samples from the same individuals
collected 1 to 9 months after the onset of symptoms was used to
represent physiologic levels after infection (termed ‘‘convales-
cent samples’’ in this report). Of the 74 cases identified, 48 (32
DF and 16 DHF patients) had convalescent samples available.
The data presented in table 1 do not include all the information
obtained from each patient and are not intended to define the
clinical classification. The platelet data presented in the table
g i v et h ec o u n to nt h ed a yo ft h es a m p l eu s e di nt h i ss t u d ya n d
not the lowest count found in that particular patient. All DHF
patients had thrombocytopenia at some time point. As a normal
reference, we used samples from 30 healthy individuals, who
were identified as eligible to receive yellow fever vaccine. The
samples used here were collected from these individuals before
immunization.
Ethical considerations
Written consent to participate in the study was obtained from
each patient (or the patient’s guardian) after a full explanation of
the study was provided. All data were handled confidentially and
anonymously. This study was reviewed and approved by the ethics
committee of the Brazilian Ministry of Health (CONEP: 4909;
Process nu 25000.119007/2002-03; CEP: 68/02). In addition, the
Johns Hopkins University Institutional Review Board reviewed
and approved the study as protocol JHM-IRB-3: 03-08-27-01.
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Patient ID Age Sex
Days of symptoms
(acute phase)
Days of symptoms
(conv. phase)
Type of
Infection
Clinical
Diagnosis
Platelet/mm
3610
3
(acute phase)
P141 30 F 3 - Primary DF -
P151 42 F 3 - Primary DF 209
P161 30 M 3 - Primary DF -
P363 24 F 3 255 Primary DF 246
P388 23 F 5 255 Primary DF 172
P411 47 F 3 255 Primary DF 160
P412 56 M 3 255 Primary DF 206
P423 48 F 3 - Primary DF 153
P426 30 F 6 - Primary DF 224
P456 40 M 3 31 Primary DF 214
P475 34 F 5 33 Primary DF 178
P486 52 F 7 21 Primary DF 350
P524 27 F 4 178 Primary DF 149
P545 22 M 5 255 Primary DF 162
P588 15 M 3 - Primary DF 148
P591 37 F 5 - Primary DF 224
P593 41 M 6 31 Primary DF 277
P598 13 F 4 255 Primary DF -
P664 43 F 8 255 Primary DF 257
P098 23 F 3 - Secondary DF 242
P107 41 M 5 - Secondary DF 141
P129 43 F 3 - Secondary DF 229
P301 13 F 4 24 Secondary DF 215
P308 48 M 8 255 Secondary DF 170
P310 33 F 3 31 Secondary DF 90
P321 19 F 7 255 Secondary DF 269
P330 19 F 4 255 Secondary DF 143
P348 13 F 5 50 Secondary DF 156
P356 62 M 8 31 Secondary DF 232
P361 27 M 4 255 Secondary DF 194
P374 18 M 8 32 Secondary DF 196
P382 50 M 5 255 Secondary DF 162
P435 40 M 5 32 Secondary DF 153
P446 35 M 3 255 Secondary DF -
P481 49 F 5 255 Secondary DF 140
P488 37 F 4 30 Secondary DF 151
P504 46 F 3 - Secondary DF 200
P509 47 M 5 - Secondary DF 191
P511 53 F 8 - Secondary DF 223
P550 52 F 6 255 Secondary DF 184
P578 35 M 5 - Secondary DF 232
P582 49 M 5 255 Secondary DF 234
P600 26 M 6 - Secondary DF 284
P604 47 M 5 255 Secondary DF 174
P620 58 M 8 255 Secondary DF 141
P623 38 F 5 255 Secondary DF 144
P659 32 F 8 255 Secondary DF 274
P094 49 F 6 - Primary DHF 70
P102 25 F 5 255 Primary DHF 72
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Days of symptoms
(acute phase)
Days of symptoms
(conv. phase)
Type of
Infection
Clinical
Diagnosis
Platelet/mm
3610
3
(acute phase)
P111 15 F 5 255 Primary DHF 105
P128 45 F 3 255 Primary DHF 148
P145 18 M 5 - Primary DHF 90
P165 33 F 4 - Primary DHF 178
P260 13 F 8 255 Primary DHF 37
P305 45 M 4 255 Primary DHF 80
P307 41 F 8 255 Primary DHF 80
P339 47 F 6 - Primary DHF 87
P370 48 M 7 142 Primary DHF 81
P430 34 F 6 - Primary DHF 49
P564 36 F 3 - Primary DHF 136
P613 47 F 5 255 Primary DHF 42
P635 26 F 6 35 Primary DHF 81
P104 47 F 8 255 Secondary DHF 48
P125 19 F 6 - Secondary DHF 64
P193 22 F 5 - Secondary DHF 91
P206 12 M 3 255 Secondary DHF 122
P277 48 M 3 255 Secondary DHF 134
P420 76 F 4 - Secondary DHF 248
P428 57 M 3 255 Secondary DHF 75
P543 27 F 7 - Secondary DHF 89
P549 58 F 6 32 Secondary DHF -
P586 56 F 5 255 Secondary DHF 115
P629 17 M 4 19 Secondary DHF 87
HC01 49 F - - - - -
HC02 47 F - - - - -
HC03 49 M - - - - -
HC04 47 F - - - - -
HC05 37 M - - - - -
HC06 27 M - - - - -
HC07 26 F - - - - -
HC08 20 F - - - - -
HC09 48 M - - - - -
HC10 20 F - - - - -
HC11 51 M - - - - -
HC12 38 M - - - - -
HC13 24 M - - - - -
HC14 27 M - - - - -
HC15 37 M - - - - -
HC16 79 M - - - - -
HC17 38 F - - - - -
HC18 57 M - - - - -
HC19 43 M - - - - -
HC20 44 M - - - - -
HC21 37 M - - - - -
HC22 31 M - - - - -
HC23 31 M - - - - -
HC24 28 M - - - - -
HC25 38 M - - - - -
Table 1. Cont.
Role of Factors D & H in DHF
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6782Quantitative ELISA Protocols
Purified human complement protein C1q (Quidel), a chicken
polyclonal antiserum against human C1q (Abcam), and HRP-
conjugated sheep anti-human C1q (AbD Serotec) were used to
measure C1q in plasma samples. A standard curve was established
using a nonlinear regression curve (R
2.0.95) with seven standard
concentrations; the range of detection was 0.0001–10.0 mg/mL.
Purified human factor H (Calbiochem), a goat polyclonal
antiserum against human factor H (Calbiochem), a mouse
monoclonal antiserum [HYB 268] against human factor H
(Abcam), and HRP-conjugated goat anti-mouse IgG (Jackson
Immunoresearch) were used to measure factor H. A standard
curve was established using a linear regression curve (R
2.0.95)
with five standard concentrations; the range of detection was 3–
25 ng/mL. Purified human complement protein C3 (Quidel), a
chicken polyclonal antiserum against human complement C3
(Genway), rabbit polyclonal antiserum against human C3
biotinylated (Abcam), and HRP-conjugated streptavidin (Rock-
land) were used to measure C3. A standard curve was established
using a nonlinear regression curve (R
2.0.95) with seven standard
concentrations; the range of detection was 0.0001–10.0 mg/mL.
The plasma samples were diluted so that the values obtained fell
within the standard curves.
Nunc microplates were coated with primary antibody and
diluted in carbonate/bicarbonate buffer, pH 9.6. After washing
with PBS (pH 7.2) containing 0.05% Tween 20 (PBS-T), the plates
were blocked with 5% BSA (Sigma) for 1 h at 37uC. They were
then washed again and incubated for 2 h at 37uC with either the
plasma samples from dengue patients or with purified protein, in
duplicate. The plates were again washed and incubated for 1 h at
37uC with secondary antibody. When a tertiary step was
necessary, the plates were washed and incubated for 1 h at 37uC
with HRP-conjugated component (antibody or streptavidin). After
a final wash, the plates were developed with TMB (BD
Biosciences) and read at 450 nm in a microplate reader (Safari
2,
Tecan).
Immunoassays for Complement Factor D,
Anaphylotoxins, MBL Oligomers, Immunocomplexes, and
C-Reactive Protein
Plasma levels of complement factor D, anaphylotoxins, MBL
oligomers, and total IgG immunocomplexes (CIC-C1q) were
measured using the Duo Set ELISA development kit for human
factor D (R&D systems), the Cytometric Bead Array kit for human
anaphylotoxin (BD Biosciences), the MBL oligomer ELISA kit
(Innate Immunity Diagnostics), and the CIC-C1q ELISA kit
(Quidel), respectively, according to manufacturer directions. C-
reactive protein was measured by immunoturbimetry using a
Hitachi 912 (Roche Diagnostics).
Statistical Analysis
Statistical analysis and plotting were carried out using Prism
version 4 and R version 2.9.0 for Macintosh. In order to ensure
that the data are Gaussian-distributed, concentration values of
each complement protein were log-transformed. Gaussianity of the
log-tranformed data was confirmed by means of cumulative
frequency distribution plots and the Kolmogorov-Smirnov test
(data not shown). Two-tailed unpaired t-tests were then used to
compare the averages of concentration of different proteins,
whereas two-tailed paired t-tests were used to compare the levels of
different complement components in the same individual at
different stages of infection (acute and convalescence). Pearson’s
correlation was used to assess the co-variation among the groups
analyzed. Differences were considered statistically significant when
p,0.05.
In order to quantify the imbalance in levels of factor H and
factor D across different diagnostic categories, log-ratios between
the concentration of factor H over the concentration of factor D
were computed. Factor D acts by cleaving BB in the C3bBB
complex to yield active C3bBb, whereas factor H regulates C3bBb
by displacing the Bb portion of this C3 convertase, thus having the
opposing effect of inactivating the AP convertase. If the log-ratios
in concentration of factor H over factor D tend to be larger in a
given diagnostic category than in the healthy category, then we
may conclude that the balance between factors D and H is less
favorable for the formation of the C3bBb C3 convertase in that
diagnostic category than in healthy individuals, whereas smaller
log-ratios mean that the balance is more favorable. Thus, the log-
ratios in concentration of factor H over factor D allow the study of
how these two proteins are regulating the alternative pathway
C3bBb C3 convertase levels, however it does not directly indicate
the amount of active convertase.
Results
DHF patients show elevated complement activity and C3
consumption
During complement activation, C3 is cleaved to form C3a and
C3b; when C3 is cleaved faster than it can be replaced, the levels
of intact C3 decay. This phenomenon often occurs when the
complement system is highly active. In the present study, we
measured the levels of C3 in the DF and DHF patients during the
acute phase and compared their levels to those of control patients
(Figure 1A, Table 2). The C3 levels in the DF patients in the acute
phase were nearly identical to those in the healthy subjects (1.5+/
Patient ID Age Sex
Days of symptoms
(acute phase)
Days of symptoms
(conv. phase)
Type of
Infection
Clinical
Diagnosis
Platelet/mm
3610
3
(acute phase)
HC26 49 F - - - - -
HC27 19 M - - - - -
HC28 46 M - - - - -
HC29 33 M - - - - -
HC30 34 M - - - - -
DF – dengue fever; DHF – dengue hemorrhagic fever; Prim – primary infection; Sec – secondary infection; SD – standard deviation. Note: the platelet count is the one
obtained at the day of the sample used in the complement factor measurements. It is not the lowest level found in the patient.
doi:10.1371/journal.pone.0006782.t001
Table 1. Cont.
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C3 levels in DHF patients (1.0+/20.6 mg/mL) were significantly
(p=0.002) lower than those in the DF patients during acute
dengue infection and also significantly (p=0.0006) lower than the
C3 levels in the healthy control group. In order to determine
whether the lower levels of C3 were indeed the result of high levels
of complement system activity during infection, the C3 levels of
the DHF patients were also measured during the convalescent
phase (Figure 1B). The data showed a significant (p=0.005)
increase in the C3 levels of the DHF patients after they recovered
from the acute infection, and these levels were not significantly
different from the levels found in control patients, confirming that
the C3 was consumed at higher levels in DHF patients than in DF
patients during the acute stage of the dengue infection.
In addition, we have performed analyses comparing the C3
levels on primary vs. secondary dengue infection and no significant
differences were detected. Similarly we tested the effect of dengue
infection history on the other complement factors we measured
and we have not detected any influence within each clinical
diagnosis assessed.
DHF patients have elevated levels of the anaphylotoxins
C3a and C5a
We also measured the plasma levels of C3a, a product of C3
cleavage, and C5a, a product of C5 cleavage, in samples from
patients with confirmed dengue infection and different clinical
diagnoses (Figure 2). Both C3a (Figure 2A) and C5a (Figure 2B)
were present at approximately three-fold higher levels in the DHF
Figure 1. Levels of complement factor 3 (C3); plotted values are nonlog for ease of comprehension. (A) Plasma C3 levels in dengue-
infected individuals during the acute phase (3–8 days after the onset of symptoms) and in healthy subjects. (B) Paired C3 levels of DHF patients
during the acute and convalescent phases of dengue infection. The mean of C3 levels for acute and convalescence were 1.0+0.5 and 1.4+0.3
respectively. The C3 levels were measured by ELISA. Values shown are means and standard deviations. The p-values of two-tailed t-tests on the log-
transformed data are indicated above each analysis.
doi:10.1371/journal.pone.0006782.g001
Table 2. Levels of different components of the complement system in plasma samples collected from dengue-infected patients
with different clinical manifestations and at different stages of infection.
Complement proteins Healthy Control DF DHF
Acute Con Acute Con
C1q (mg/mL) 1069 22619* 11671 8 623 963
MBL (mg/mL) 3.261.9 2.863.2 3.162.3 4.464.2 3.363.4
CRP (mg/dL) 0.260.2 1.161.6* 0.260.2 1.061.3* 0.160.2
CIC-C1q (mg Eq/mL) ND 1686153 ND 1496115 ND
CFH (mg/mL) 2066123 2336192 2026103 142692* 213681
CFD (ng/mL) 7616204 6256343* 7046278 8046337 8466397
C3 (mg/mL) 1.560.8 1.560.9 1.360.3 1.060.6* 1.460.3
Values shown are means and standard deviations.
DF – dengue fever; DHF – dengue hemorrhagic fever; Acute – acute phase; Con – convalescent phase; CRP – C-reactive protein; CIC-C1q – IgG immunocomplex; CFD –
factor D; CFH – factor H; HC – healthy control; ND – non-determined. * Indicate the significant (p#0.05) differences between dengue patients with health controls.
doi:10.1371/journal.pone.0006782.t002
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significant (p,0.001). The elevated levels of C3a and C5a that we
observed in DHF patients are consistent with their decreased levels
of C3 and further confirm the association of high complement
activity with DHF.
The increased complement activation in DHF patients is
correlated with MBL oligomerization, but not correlated
with levels of immune complexes, C1q or CRP
The increased consumption of C3 and elevated levels of
byproducts of complement activation (C3a and C5a) that we
observed in DHF patients confirmed that higher complement
activation is correlated with dengue severity. However, the pathway
of complement activation was not defined. Therefore, we measured
thelevelsofC4a,whichcorrelates withthe formationofthe(C4b2b)
C3 convertase, a hallmark for activation of the CP or LP (Figure 3).
This result indicates that C4a was 3-fold elevated in DHF patients
suggesting the involvement of either the CP or the LP. In order to
identify the mechanism of the CP or LP activation we measured
levels of C1q, CRP, CIC-C1q and oligomerized MBL in plasma
samples from DF and DHF patients (Figure 4; Table 2). The levels
of C1q and CRP in the DF and DHF patients were elevated during
acute infectionwhen compared to healthy control subjects, andthey
returned to normal levels during convalescence. However, levels of
both proteins were similar between DF and DHF patients. There
was also no difference in the total IgG immunocomplex levels (CIC-
C1q) during the acute phase between the DF and DHF patients.
This result suggests that the activation of the (C4b2b) C3 convertase
was not mediated by differences on the levels of immune complexes
in DF and DHF patients. However, other factors, such as significant
differences in the IgG isotype distribution in the two groups could
interfere with the interpretation of this result, since different
immunoglobulins have different capacities to activate the CP.
The activity of the LP was evaluated by measuring the levels of
oligomerized MBL, and a significant increase of MBL oligomer-
ization was found in the DHF patients as compared to the DF
patients during the acute phase of infection, which might have
contributed to the elevated C4a level. These observations suggest
that it is possible that MBL can be contributing to the increased
activation of (C4b2b) C3 convertase in DHF through mechanisms
that do not involve immune complexes.
Higher complement activation in DHF patients is
associated with abnormal levels of regulatory AP factors
Quantitation of two AP components, factors D and H, in DF,
DHF, and control patients (Figure 5, Table 2) revealed that the
levels of factor D were significantly (p=0.01) lower in DF patients
than in DHF patients during acute infection and also lower than
Figure 2. Levels of complement factors C3a and C5a; plotted values are nonlog for ease of comprehension. (A) Plasma levels of C3a and
(B) C5a in dengue-infected individuals during the acute phase and in healthy subjects. C3a and C5a levels were measured by cytometric bead assay.
Values shown are means and standard deviations. The p-values of two-tailed t-tests on the log-tranformed data are indicated above each analysis.
doi:10.1371/journal.pone.0006782.g002
Figure 3. Levels of C4a; plotted values are nonlog for ease of
comprehension. Plasma levels of C4a in dengue-infected individuals
during the acute phase and in healthy subjects. C4a levels were
measured by cytometric bead assay. Values shown are means and
standard deviations. The p-values of two-tailed t-tests on the log-
transformed data are indicated above each analysis.
doi:10.1371/journal.pone.0006782.g003
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phase, the mean factor D levels in the DF patients returned to that
of DHF patients and control subjects (Figure 5B), suggesting that
the levels of factor D in DF patients were reduced during acute
dengue infection, limiting the rate of conversion of the C3bBB into
the active C3 convertase, C3bBb, in these patients.
In contrast, the levels of factor H, which displaces Bb from
C3bBb and inactivates the C3 convertase, were significantly
lower (p=0.03) in DHF patients than in DF patients during
acute infection (Figure 5C). The levels of the factor H in DHF
patients were also significantly lower (p=0.01) than those in
healthy individuals, whereas in DF patients, this was not
observed. During the convalescent phase, the levels of factor H
in the DHF patients had returned to the levels seen in healthy
controls (Figure 5D). These data indicate a reduced ability to
inhibit the amount of C3bBb C3 convertase in DHF patients.
Taken together, the data regarding factors D and H suggest that
DHF patients have a reduced ability to regulate the activity of
the AP.
Based on the fact that factors D and H act together to influence
the availability of the C3 convertase and consequently the
activation of the complement system through this pathway, we
analyzed the levels of both proteins in each patient through the
log-ratio of their concentrations, as described in the Materials and
Figure 4. Levels of factors of the CP and LP; plotted values are nonlog for ease of comprehension. (A) Plasma levels of C1q, (B) MBL
oligomer, (C) C-reactive protein, and (D) immunocomplex-CIC-C1q in dengue-infected individuals at different stages of infection (acute and
convalescent) and in healthy subjects. All complement proteins were measured by ELISA. Values shown are means and standard deviations. The p-
values of two-tailed t-tests on the log-transformed data are indicated above each analysis.
doi:10.1371/journal.pone.0006782.g004
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PLoS ONE | www.plosone.org 8 August 2009 | Volume 4 | Issue 8 | e6782Methods. The results of this analysis indicated that DF and DHF
patients exhibited strikingly different patterns of AP activity during
acute dengue infection (Figure 6). In this figure, a value of zero
indicates that the levels of both factors were at proportions similar
to that seen in healthy (ND) control subjects, negative values
indicate a greater proportion of factor D in relation to factor H,
and positive values indicate the opposite. The acute DF patients
showed significantly (p=0.046) larger log-ratios in relation to
healthy controls, whereas the acute DHF patients showed
significantly (p=0.009) reduced log-ratios when compared to
healthy controls. The difference in log-ratios between the acute
DF with DHF patients was highly significant (p,0.0001). During
the convalescent phase, the log-ratios of the DF and DHF patients
approximated of those of the control group, and no significant
differences were detected (Figure 6). Further supporting the
association of the AP regulatory proteins with dengue disease
severity, levels of C3 levels and factor H were higly correlated
(Figure 7). These results suggest that during acute dengue
infection, the regulatory proteins of the AP are modulated in
order to maintain the homeostasis of complement activity, and
when an imbalance between levels of factor D and factor H
occurs, during the acute phase of the infection, the regulation of
this pathway is decreased, leading to an abnormal activation of the
complement system.
Figure 5. Levels of AP factors; plotted values are nonlog for ease of comprehension. (A) Plasma levels of factor D and (B) factor H in
dengue-infected individuals and healthy subjects. (C) Paired comparisons of the factor D levels during the acute and convalescent phases in DHF
patients. The mean levels of factor D on DF patients was 555+246 and 704+278 during acute and convalescence phases respectively (D) Paired
comparisons of factor H levels during the acute and convalescent phases in DF patients. The mean levels of factor H on DHF patients was 138+49 and
210+83 during acute and convalescence phases respectively All complement proteins were measured by ELISA. Values shown are means and
standard deviations. The p-values of two-tailed t-tests on the log-transformed data are indicated above each analysis
doi:10.1371/journal.pone.0006782.g005
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pathway components are correlated with reduced
platelet levels
Platelet levels are reduced during acute dengue infection (both DF
and DHF), and thrombocytopenia is associated with an increased
severity of the dengue infection. The main mechanisms that have been
proposed to account for the induction of thrombocytopenia in dengue
infection include virus-mediated megakaryocyte suppression in the
bone marrow [21] and increased platelet destruction [22–24]. In the
present analysis,theC3 levels were found tobedirectlycorrelated with
platelet levels and inversely correlated with C3a and C5a levels
(Table 3), indicating that the higher the complement system activity is,
the lower the platelet level during acute dengue infection is. Factor H
was also highly correlated with platelet levels in the dengue patients,
whereas C1q, CIC-C1q, CRP, and MBL protein levels were not
(Table 3). These results further support our conclusion that abnormal
modulation of AP regulatory proteins is a significant factor
contributing to dengue severity.
Discussion
The levels of C3, C3a, and C5a that we have measured in
dengue patients (Figures 1 and 2) demonstrated the presence of
Figure 6. Mean log-ratios of concentration of factor H over the concentration of factor D for each diagnostic category, subtracted
from the mean log-ratio in the healthy (ND) category. A value of zero indicates that the levels of both factors were present in the same
equilibrium as in healthy control subjects. Negative values indicate reduced AP regulation and favorable formation of (C3aBb) C3 convertase, whereas
positive values indicate the opposite. The standard deviation bars give the interval (mean + err, mean –err), where err is the usual standard error of
difference between sample means, except in the baseline (ND) category, where err is the standard error of the sample mean for that category.
doi:10.1371/journal.pone.0006782.g006
Figure 7. Correlation between levels of factor H and C3. Analysis
of correlation was carried out between log-transformed levels of factor
H and C3 dengue-infected patients during the acute phase.
doi:10.1371/journal.pone.0006782.g007
Table 3. Correlations between individual components of the
complement system and platelet count in dengue-infected
patients during the acute phase.
Protein Pearson r
95% confidence
interval p value R
2
Factor H (ug/mL) 0.260 0.021 to 0.471 0.033 0.068
Factor D (ng/mL) 20.111 20.342 to 0.132 0.370 0.012
C1q (ug/mL) 0.194 20.049 to 0.414 0.117 0.037
MBL (ug/mL) 20.133 20.360 to 0.109 0.280 0.018
CIC-C1q (E/mL) 20.009 20.283 to 0.267 0.951 0.000
CRP (mg/dL) 20.022 20.278 to 0.238 0.872 0.000
C3 (mg/mL) 0.329 0.094 to 0.529 0.007 0.108
C3a (ug/mL) 20.525 20.735 to 20.221 0.002 0.275
C5a (ng/mL) 20.494 20.707 to 20.197 0.002 0.244
C4a (ng/mL) 20.1140 20.4266 to 0.2230 0.5081 0.01299
Proteins in boldface type were significantly (p,0.05) correlated with platelet
levels.
doi:10.1371/journal.pone.0006782.t003
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consistent with the levels that have been previously reported in
patients with this severe form of disease [3,11,13,14]. Our analysis
of pathway-specific components of the complement system has
suggested that immunocomplexes do not appear to be involved
with the abnormal activation of the complement system in DHF
patients. However, the complement factors D and H (Figures 5;
Table 2), key regulatory proteins of the AP, are present in
abnormal levels in DHF patients and an imbalance between the
levels of these proteins is correlated with disease severity. The lack
of proper regulation of the AP convertase may be responsible for
the increased complement activation that has been observed in
DHF patients (Figure 6; Table 3).
Factor D, also termed adipsin, is a rate limiting serine protease
produced by adipocytes, monocytes, and macrophages [25]. It
circulates in active form and is responsible for cleaving BB in the
C3bBB complex to produce C3bBb, the active C3 convertase of
the AP. Factor D is considered as one of the limiting factors for the
activation of the alternative pathway [26]. In our study, levels of
factor D in DF patients were lower than those in either DHF
patients or healthy controls (Figure 5A), whereas during the
convalescent phase, levels of factor D in DF patients were as high
as those found in DHF patients during convalescent (Figure 5B).
These data suggest that during acute dengue infection, the patients
who are more capable of modulating their levels of factor D will
exhibit the mild disease phenotype DF. In contrast, it appears that
when levels of factor D are not reduced, the patient develops the
most severe form of the disease DHF (Table 2).
Although factor D appears to play a role in determining dengue
severity, factor H is also widely regarded as one of the most
important regulator of the AP. During acute infection, the plasma
levels of factor H in DHF patients were lower than those in either
DF patients or healthy subjects (Figure 5C), but they returned to
normal levels during convalescence (Figure 5D). In contrast, the
levels of factor H did not change in the DF patients (Table 2). One
possibility is that DHF individuals have a limited capacity to
sustain normal factor H levels during acute dengue infection
because of genetic factors. Indeed, preliminary data from Acioli-
Silva et al. [27] have suggested that individuals with a
polymorphism that is associated with increased mRNA expression
of factor H have a reduced susceptibility to developing DHF.
Factor H gene dysfunctional polymorphisms have been associated
with vascular diseases such as age-related retinal degenerative
maculopathy and atypical hemolytic uremic syndrome (aHUS)
[28–30], and the occurrence of these clinical manifestations has
also been described in severe dengue cases [31,32]. In addition,
the fact that infants normally produce less factor H than do adults
[33] and that this age group is more affected by DHF [34] also
supports a possible role for this complement factor in determining
dengue severity. Interestingly, studies on NS1 protein from West
Nile virus have shown that this protein can bind to factor H,
recruiting this complement protein to the surface of infected cells,
allowing NS1 bound cells to escape from complement-mediated
lyses [15]. However, this mechanism has not been shown to be
happening during dengue infection.
On the basis of the evidence obtained so far, especially due to
the presence of elevated C4a, we cannot rule out the possibility
that CP and/or LP are also involved in determining dengue
severity. In the report presented by Bokish et al, the consumption
of C4 was mild in DHF patients grades I and II, suggesting that
the (C4b2b) is not the main C3 convertase involved in the
complement activation in the milder DHF these cases. The
(C4b2b) C3 can be activated by several mechanisms including
immune complexes, CRP, Specific ICAM-3 Grabbing Non-
Integrin (SIGN-1), phosphatidyl serine, complex polysaccharides,
and others. Often the CP is triggered by the binding of C1q to
either antibody-antigen immunocomplexes [4] or reactive-C
protein [5]. Fc-dependent complement-mediated antibody re-
sponses are one of the main humoral immune effector mechanisms
against flaviviruses, and virus opsonization is a major mechanism
of viral clearance that operates via complement receptors [2]. In
addition, C1q has been shown to restrict ADE [35,36], a critical
mechanism contributing to DHF immunopathology [37]. Thus,
the CP can potentially play an important role in dengue patient
outcomes at early stages of infection. However, neither C1q levels
neither those components that activate this protein (C-reactive
protein and IgG immunocomplexes) were correlated with dengue
severity (Figure 3); and these findings are consistent with those of
several other studies that found no evidence of abnormal levels of
immune complexes and CRP in DHF patients [14,16,38]. In
addition, our C1q finding is also consistent with the findings
reported by Bokisch. In this study the C1q values did not fall
significantly in less severe grade I and II DHF cases. Actually, in
the example shown in the Bokisch manuscript, the C1q level is
above normal at all time points [3]. In a separate study, Sobel used
the C1q deviation test and found a correlation of C1q deviation
with DHF severity. The C1q deviation test is the measurement of
the difference in incorporation of labeled C1q into sheep
erythrocytes in relation to a standard sample [39]. As the authors
pointed out, the C1q deviation assay is highly sensitive to the
presence of DNA, which can be very elevated in the serum of
dengue patients. The LP could also potentially play a role, leading
to elevated levels of C4a. Previously, we have demonstrated that
MBL2 gene polymorphism is correlated with the risk of
thrombocytopenia elicited by dengue virus [40] and in this study
we saw a significant correlation between the MBL protein and
DHF. There are other known mechanisms to activate (C4b2b) C3
convertase without involving C1q, immune complexes or MBL.
Among the interesting possibilities are some of the mechanisms
related to clearance of apoptotic bodies [41]. Kuraya and
collaborators have reported that ficolins can bind to apoptotic
cells and activate the (C4b2b) C3 convertase [42].
Individually, factors D and H showed significant differences
during acute dengue infection. But since these two factors have
antagonistic effects on the modulation of the activity of the C3bBb
C3 convertase, the elevated levels of one could compensate for the
levels of the other, we decided to analyze ratios of both factors.
The increased log-ratios in concentration between these factors in
plasma samples from patients with acute dengue infection clearly
pointed to an increase in the regulation of the AP in DF patients
and a reduced regulation of the AP in DHF patients when
compared to healthy controls. These results suggest the presence of
an increased availability of the C3bBb C3 convertase in DHF
patients that may be responsible for the higher consumption of C3
and increased production of C3a and C5a in these patients. This
observation is consistent with previous direct measures of
alternative pathway activaty reported by Bokisch et al. [3].
Our observation that levels of C3 were directly correlated with
the platelet levels and inversely correlated with C3a and C5a levels
(Table 3) is consistent with previous reports that C3 consumption
and C3a and C5a production are correlated with the thrombo-
cytopenia seen in people developing the most severe form of the
disease [43,44]. The complement factors of the CP that we
examined here did not show any direct correlation with platelet
levels; however, factor H did show strong correlation, supporting
our conclusion that the lack of AP regulation is one of the
mechanisms contributing to complement activation and disease
severity. Interestingly, factor H deficiencies are associated to
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pathy [45–49]. However, other mechanisms could also contribute
to the thrombocytopenia, since some patients have antibodies that
cross-react with platelets and endothelial cells and therefore
augment the cytotoxicity mediated by the CP [43,50].
Overall, the majority of the data presented here point to an
association between the improper modulation of AP regulatory
proteins and increased dengue severity. In addition, previous
biochemical evidence supports the existence of an association
between dengue proteins and the AP. Whereas membrane-
associated NS1 requires the presence of anti-NS1 antibodies to
achieve complement activation [11,51], soluble and purified
dengue NS1 protein has been shown to activate complement in
the absence of anti-dengue antibodies, suggesting that soluble NS1
can directly induce complement activation [11,51]. Taken
together, these data suggests that AP regulatory proteins such as
factor H and factor D, as well as their substrates, are potential
therapeutic targets to prevent the onset of DHF.
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